BridgeBio's oral infigratinib just landed FDA Priority Review for achondroplasia, with an action date of Feb 4, 2027, on Phase 3 PROPEL 3 data. Priority Review shortens the clock and this is an oral a
FDA Priority Review for infigratinib in achondroplasia signals accelerated regulatory catalyst.
BBIO
$67.94
+2.33%
What changed
FDA Priority Review for infigratinib in achondroplasia signals accelerated regulatory catalyst.
Why it matters
FDA Priority Review for infigratinib in achondroplasia signals accelerated regulatory catalyst. — impact context not separately stored; see What changed.
← Dashboard
Oct 06, 2026 03:06 PM ET